Physician profile
Whitney B Breen
NPI 1013464734
$4,150.81
in general payments reported to CMS, 2019-2025
36 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $823 · 2022: $890 · 2023: $519 · 2024: $901 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,437.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,487.26 | 2021-2025 | |
| Lilly USA, LLC | $578.52 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $364.18 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $325.15 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.81 | 2022-2025 | Caplyta |
| Amgen INC. | $141.81 | 2021-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $93.72 | 2021-2024 | |
| Abbott Laboratories | $77.45 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.54 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $67.50 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $63.95 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $60.59 | 2024-2025 | Voquezna |
| Lundbeck LLC | $59.61 | 2025 | Rexulti, Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.94 | 2021-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $43.75 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.23 | 2021-2025 | Arexvy, Shingrix |
| Viiv Healthcare Company | $42.37 | 2025 | Apretude |
| Astellas Pharma US INC | $39.01 | 2025 | Veozah |
| Organogenesis INC. | $32.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.66 | 2021 | |
| Currax Pharmaceuticals LLC | $27.99 | 2024-2025 | Contrave |
| Amneal Pharmaceuticals LLC | $22.63 | 2025 | Unithroid |
| Boston Scientific Corporation | $21.35 | 2024 | Watchman Flx |
| Scilex Pharmaceuticals INC. | $20.66 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $20.05 | 2021 | |
| Organon LLC | $19.01 | 2025 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $18.77 | 2022 | |
| Amarin Pharma, INC. | $18.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.28 | 2025 | |
| Coopersurgical, INC. | $16.32 | 2025 | Paragard T 380a |
| Eisai INC. | $15.67 | 2021 | |
| Exact Sciences Corporation | $14.68 | 2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $14.14 | 2024 | Gvoke Hypopen |
| Seqirus USA INC | $13.36 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.92 | 2021 | |
| Merck Sharp & Dohme LLC | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.